Bristol-Myers Squibb Appoints Paul Biondi Senior Vice President, Head of Business Development
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Leerink Partners Remains Bullish on Five Prime Therapeutics (FPRX) Following announced Agreement with BMY
October 15, 2015 4:06 PM EDTLeerink Partners reiterated an Outperform rating on Five Prime Therapeutics (NASDAQ: FPRX) following an announced exclusive $1.74Bn license and collaboration agreement with Bristol-Myers Squibb Company (NYSE: BMY) for the development and commercialization of FPRXs CSF1R antibody... More
Bristol-Myers Squibb (BMY) Names New Business Development SVP
October 15, 2015 2:20 PM EDTBristol-Myers Squibb (NYSE: BMY) announced that Paul Biondi has been appointed senior vice president, head of Business Development and will report to Charlie Bancroft, chief financial officer. In this role, Biondi will lead the development of strategic partnerships and pursue scientific innovations across commercial, development, discovery and technology platforms to complement the companys internal R&D pipeline. Biondi most recently served as senior vice president, head of R&D Operations, Bristol-Myers Squibb.
Paul has established himself as a dynamic and collaborative leader at Bristol-Myers Squibb and made... More
